Goldman Sachs Group Inc Myriad Genetics Inc Transaction History
Goldman Sachs Group Inc
- $706 Billion
- Q2 2025
A detailed history of Goldman Sachs Group Inc transactions in Myriad Genetics Inc stock. As of the latest transaction made, Goldman Sachs Group Inc holds 1,283,454 shares of MYGN stock, worth $10.4 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
1,283,454
Previous 714,095
79.73%
Holding current value
$10.4 Million
Previous $6.33 Million
7.59%
% of portfolio
0.0%
Previous 0.0%
Shares
22 transactions
Others Institutions Holding MYGN
# of Institutions
234Shares Held
95.2MCall Options Held
460KPut Options Held
14.2K-
Black Rock Inc. New York, NY15.2MShares$122 Million0.01% of portfolio
-
Vanguard Group Inc Valley Forge, PA9.26MShares$74.8 Million0.0% of portfolio
-
Israel Englander Millennium Management LLC | New York, Ny4.92MShares$39.8 Million0.01% of portfolio
-
State Street Corp Boston, MA4.81MShares$38.9 Million0.0% of portfolio
-
Glenview Capital Management, LLC New York, NY4.59MShares$37.1 Million0.69% of portfolio
About MYRIAD GENETICS INC
- Ticker MYGN
- Exchange NASDAQ
- Sector Healthcare
- Industry Diagnostics & Research
- Shares Outstandng 80,634,800
- Market Cap $652M
- Description
- Myriad Genetics, Inc., a genetic testing and precision medicine company, develops and commercializes genetic tests in the United States and internationally. The company offers molecular diagnostic tests for use in oncology, and women's and mental health applications. It provides MyRisk Hereditary Cancer Test, a DNA sequencing test for assessing ...